TECH — Bio-Techne Corporation

Bio-Techne Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $286.6 million, a 1% year-over-year decline (both organic and reported).
• Adjusted EPS: $0.42, flat year-over-year; GAAP EPS increased to $0.24 from $0.21.
• Adjusted Gross Margin: 70.2%, up from 69.5% last year.
• Adjusted Operating Margin: 29.9%, an increase of 90 basis points year-over-year.
• Operating Cash Flow: $27.6 million, with net capital expenditures of $5.4 million.
• Debt: Bank debt at $300 million, down $46 million sequentially.

2. Strategic Updates and Business Highlights

• Cell Therapy Business: Experienced a 1% organic revenue decline due to clinical stage timing from large customers receiving FDA Fast Track designation, which reduced near-term reagent demand.
• ProteinSimple Franchise: Continued growth momentum, particularly in China, with strong demand from large pharma customers.
• Spatial Biology Business: Resumed sequential improvement with low single-digit growth in the RNAscope product suite and strong bookings for the COMET instrument.
• Diagnostics Segment: Mid-single-digit growth driven by balanced performance across diagnostic controls and kits, with notable interest in the ESR1 test for breast cancer.

3. Forward Guidance and Outlook

• Q2 Expectations: Anticipate Q2 organic growth to be consistent with Q1, despite headwinds from cell therapy customers, projecting a 400 basis point decline due to reduced reagent purchases.
• Full-Year Outlook: Management maintains a low single-digit growth target for fiscal 2026, with expectations for stabilization and gradual improvement in the second half of the year.
• Margin Goals: Aiming for at least 100 basis points of margin expansion for the full fiscal year.

4. Challenges and Points of Concern

• Biotech Funding Pressures: Continued softness in biotech funding is impacting spending behavior, with a high single-digit decline in revenue from biotech customers.
• Cell Therapy Timing Dynamics: The lumpiness in demand due to clinical stage timing is expected to create headwinds, particularly in Q2.
• Academic Market Stability: While there are signs of stabilization, the overall funding environment remains uncertain, especially with potential impacts from government shutdowns.

5. Notable Q&A Insights

• Customer Order Timing: The headwind from FDA Fast Track designations is expected to persist into Q2, with a significant impact on growth rates.
• Market Recovery: Management is optimistic about a gradual improvement in underlying market conditions, particularly in biopharma and academic sectors.
• Wilson Wolf Acquisition: The business remains flat but is expected to accelerate as market conditions improve; the acquisition timeline may adjust based on performance milestones.
• Promotional Activities: Increased promotional efforts are being utilized to support customers during challenging market conditions, which may impact margins but are seen as necessary for maintaining customer relationships.

Overall, Bio-Techne is navigating a challenging environment with strategic initiatives aimed at long-term growth, while managing short-term headwinds in specific segments.